Captrust Financial Advisors Buys 11,871 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Captrust Financial Advisors increased its position in shares of HealthEquity, Inc. (NASDAQ:HQY - Free Report) by 117.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,959 shares of the company's stock after buying an additional 11,871 shares during the period. Captrust Financial Advisors' holdings in HealthEquity were worth $2,107,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealthfront Advisers LLC bought a new position in shares of HealthEquity during the 4th quarter worth approximately $10,304,089,000. Vanguard Group Inc. boosted its position in HealthEquity by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 8,976,091 shares of the company's stock worth $861,256,000 after purchasing an additional 99,624 shares during the period. FMR LLC increased its holdings in shares of HealthEquity by 2.4% in the fourth quarter. FMR LLC now owns 5,415,800 shares of the company's stock valued at $519,646,000 after purchasing an additional 125,684 shares during the last quarter. Geode Capital Management LLC raised its position in shares of HealthEquity by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 2,089,398 shares of the company's stock valued at $200,522,000 after purchasing an additional 10,421 shares during the period. Finally, Brown Advisory Inc. lifted its stake in shares of HealthEquity by 12.0% during the 4th quarter. Brown Advisory Inc. now owns 2,086,026 shares of the company's stock worth $200,154,000 after buying an additional 224,016 shares during the last quarter. 99.55% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other HealthEquity news, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $77.65, for a total value of $446,487.50. Following the transaction, the director now owns 84,969 shares in the company, valued at $6,597,842.85. The trade was a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Henry Fiore sold 8,881 shares of the company's stock in a transaction that occurred on Friday, April 4th. The stock was sold at an average price of $78.26, for a total transaction of $695,027.06. Following the transaction, the executive vice president now owns 56,655 shares of the company's stock, valued at approximately $4,433,820.30. This represents a 13.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company's stock.

HealthEquity Price Performance

Shares of NASDAQ HQY traded up $0.58 during mid-day trading on Friday, reaching $98.23. The company had a trading volume of 815,837 shares, compared to its average volume of 793,557. The firm has a market cap of $8.50 billion, a price-to-earnings ratio of 90.12, a PEG ratio of 1.60 and a beta of 0.45. The business's 50-day simple moving average is $87.83 and its 200 day simple moving average is $96.89. HealthEquity, Inc. has a one year low of $65.01 and a one year high of $115.59. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.20 and a current ratio of 3.20.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. KeyCorp decreased their price target on shares of HealthEquity from $110.00 to $100.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 16th. Barrington Research reaffirmed an "outperform" rating and issued a $112.00 target price on shares of HealthEquity in a research report on Friday, April 11th. The Goldman Sachs Group dropped their price target on HealthEquity from $107.00 to $94.00 and set a "neutral" rating for the company in a report on Thursday, March 27th. Raymond James upgraded HealthEquity from an "outperform" rating to a "strong-buy" rating and reduced their price target for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. Finally, Wells Fargo & Company increased their price objective on HealthEquity from $110.00 to $125.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $111.75.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.